Another Priority Review Voucher Sold
In August, AbbVie (NYSE: ABBV) paid a record-setting $350 million to United Therapeutics Corp. (NASDAQ: UTHR) for its Rare Pediatric Disease Priority Review Voucher. The fast-track voucher was awarded by the FDA as part of its approval of Unituxin™ (dintuximab), for the treatment of neuroblastoma. On Sept. 8, the FDA cleared Wellstat Therapeutics’ Xuriden (uridine triacetate) for the treatment of hereditary orotic aciduria, a rare, potentially fatal genetic disorder. It also granted a Rare Pediatric Disease Priority Review Voucher to the privately held Wellstat. That voucher was immediately sold to AstraZeneca (NYSE: AZN) as part of an agreement made in September 2014. Financial... Read More »Personalized Medicine Isn’t All Biotech
There are many sides to personalized medicine, and genetic testing is just one. Another cropped up last week in an acquisition made by Restore Health, a privately held Wisconsin company that provides personalized medicines to health care providers across the United States. Its target was Diplomat Pharmacy’s (NYSE: DPLO) compounding pharmacy business, which includes preparation of personalized medicines for patients, and compounding pharmacists who work with prescribers to customize medication to meet specific patient health needs. The deal frees up Diplomat to focus on its core specialty pharmacy operations, which were bolstered with its acquisition of Burman’s Specialty Pharmacy for $82.8... Read More »Behavioral Health Care M&A in 2015
It’s only mid-September, but the number of behavioral health care transactions is approaching last year’s total—and is likely to surpass it. Through September 11, we’ve recorded 21 deals in this sector, compared with 2014’s total of 22, which was the highest number of deals since 2006’s total of 24 transactions. American Addiction Centers (NYSE: AAC) and Acadia Healthcare Company (NASDAQ: ACHC) made four deals apiece, and six private equity firms, including Flexpoint Ford, Kohlberg and Company and Revelstoke Capital Partners, made one acquisition apiece. YearTotal DealsTotal Dollars 2015*21$474 million 201422$2.2 billion 201318$136 million 201217$1.0 billion 201114$314 million * through... Read More »Telehealth Attracts Big Players
At every healthcare deal making conference we attend, some speaker or moderator inevitably declares, “Telehealth is the wave of the future.” Those observations are coming true, based on the deals we’ve seen in 2015. Last week, Cox Communications, the broadband/cable giant from Georgia, added Trapollo LLC, a privately held nationwide telehealth and remote monitoring company to its growing arsenal of telehealth companies under Vivre Health umbrella. Cox teamed up with Cleveland Clinic earlier this year to form Vivre Health, and invested in HealthSpot, a telehealth technology company that also added Xerox (NYSE: XRX) as an investor last November. Trapollo is wholly owned by Cox, which is... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
